PTC Therapeutics (PTCT) Misses Q3 EPS by 22c, Revenue Beats

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.53), $0.22 worse than the analyst estimate of ($1.31). Revenue for the quarter came in at $217.1 million versus the consensus estimate of $178.9 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold